Viking Therapeutics (NASDAQ: VKTX) is a much-loved stock on Wall Street. It's trading at around $30 a share at the time of ...

・Raymond James reiterated a 'Strong Buy' rating and $118 price target, implying a 258% upside ahead of earnings. ・Consensus estimates expect a GAAP loss per share of $1.03, wider than last year’s $0.4 ...

Viking Therapeutics (VKTX) pushes GLP-1/GIP VK2735 into late-stage trials, but differentiation vs Zepbound is limited—read ...

CEO Brian Lian said monthly VK2735 must preserve weight loss without restarting nausea, vomiting and other gastrointestinal effects.

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session ...

Investors are now awaiting results from an early-stage study of VK2735 testing different ways to keep weight off after an initial course of treatment.

Viking Therapeutics completed enrollment of the VK2735 maintenance study in January and is set to report results in Q3'26. The maintenance study will provide multiple efficacy and tolerability ...

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options become available today, for the December 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in General Motors Co (Symbol: GM), where a total of 73,915 contracts have traded so far, ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...